Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction.Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million Series…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
